🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. EXEMESTANE, ANASTROZOLE, LETROZOLE

    Ningbo Cancer Hospital

    Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse

    phase 2 small molecule active

    1 trial

  2. EXEMESTANE, ANASTROZOLE, LETROZOLE, TAMOXIFEN

    Ningbo Cancer Hospital

    Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.

    phase 2 small molecule active

    1 trial

  3. Eculizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Kidney Transplantation

    phase 2 small molecule active

    1 trial

  4. Edaravone Dexborneol

    The First People's Hospital of Lianyungang

    Stroke, Ischemic

    phase 2 small molecule active

    1 trial

  5. Efbemalenograstim alfa Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary/Secondary Prevention

    phase 2 small molecule active

    1 trial

  6. Ejiao compound

    The First People's Hospital of Lianyungang

    Postpartum Anemia

    phase 2 small molecule active

    1 trial

  7. Elritercept

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule active

    2 trials

  8. Eltrombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

  9. Eltrombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thrombocytopenia Purpura

    phase 2 small molecule completed

    1 trial

  10. Enasidenib Mesilate, Enasidenib Mesilate, Ivosidenib, Vidaza 25 mg/ml powder for suspension for injection

    Celgene Europe Limited

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  11. Endostar

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Neoplasms

    phase 2 small molecule active

    2 trials

  12. Endostar

    The First People's Hospital of Lianyungang

    Brain Metastases

    phase 2 small molecule active

    1 trial

  13. Endostar

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  14. Endostatins

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  15. Enema transplant of fecal microbiota 25g/100mL

    Pari Pharma GmbH

    Austistic spectrum disorder

    phase 2 small molecule active

    1 trial

  16. Enema transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  17. Engineered Mitochondrial Vaccine (IMP3-Mito)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  18. Enoxaparin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pregnancy Related

    phase 2 small molecule active

    1 trial

  19. Enrolled patients with blast-phase chronic myeloid leukemia received a reduced-toxicity conditioning regimen containing thiotepa, melphalan, and fludarabine prior to undergoing allogeneic hematopoie

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CML,Blast Phase

    phase 2 small molecule active

    1 trial

  20. Ensartinib

    The First People's Hospital of Lianyungang

    Solid Tumors

    phase 2 small molecule active

    1 trial

  21. Ensartinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Ensartinib group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  23. Envafolimab

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  24. Envafolimab

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources